@aaron.endres's peptide reconstitution tips, fact-checked
Quick answer
The video demonstrates reconstitution of what is almost certainly retatrutide (LY3437943), a triple receptor agonist in Phase 3 clinical trials that is not FDA-approved or legally available as a compounded prescription in the U.S. The creator's concentration math (20 units per milligram from a 5mg vial in 1mL bac water) is arithmetically correct, but his verbal explanation is garbled in a way that creates real dosing confusion risk. Retatrutide's dose-dependent adverse event profile, including nausea, vomiting, and potential cardiovascular effects, makes unmonitored self-dosing based on a social media video a meaningful safety concern.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @aaron.endres actually say?
Aaron walked through how to reconstitute what he calls "redder" — a thinly veiled reference to retatrutide — using bacteriostatic water and an insulin syringe. His core instructions: pull 100 units of bac water into a 100-unit insulin syringe, inject it slowly down the side of the vial, rotate gently rather than shaking, and then calculate doses as 20 units per milligram from a 5mg vial. He also plugged Nova Peptides as his sourcing choice, calling them his "trusted source."
The video has 1.2 million views. That reach matters here, because retatrutide is not approved by the FDA, is not legally available by prescription in the United States, and the people watching this are almost certainly self-administering a research compound without medical supervision.
Does the science back this up?
The reconstitution technique itself is largely sound. The math, however, has a significant error that could lead to serious dosing mistakes. Retatrutide (LY3437943) is a triple GIP/GLP-1/glucagon receptor agonist that showed meaningful weight loss in Phase 2 trials, but it is still in clinical development.
The Jastreboff et al. 2023 study published in the New England Journal of Medicine tested retatrutide doses between 1mg and 12mg weekly in people with obesity. The drug produced dose-dependent weight loss but also dose-dependent GI side effects including nausea, vomiting, and diarrhea. In that trial, doses were titrated slowly by trained clinicians over many weeks. There is no published data on the safety profile of self-administered compounded retatrutide outside of controlled clinical settings, and that gap is not a small one.
What did they get wrong (or right)?
Credit where it is due: injecting bac water down the side of the vial rather than directly into the powder is standard reconstitution practice and reduces the chance of protein degradation. Gentle rotation over shaking is also correct. Alcohol swabbing both stoppers is basic sterile technique that many amateur reconstitution videos skip entirely.
Here is what he got wrong, and it matters. He says "one milligram is 22 milligrams will be 40 units." That sentence is incoherent, but if you follow his logic: 100 units of bac water into a 5mg vial means each milligram equals 20 units. That math actually checks out for 20 units per milligram. But then he says "2 milligrams will be 40 units" in a garbled way that could easily be misread. Anyone who miscalculates concentration here is not off by 10 percent, they could be injecting a multiple of their intended dose. At retatrutide's potency range, that is a meaningful clinical risk.
His sourcing plug for "Nova Papsler" (Nova Peptides) is unverified by any independent third-party analysis presented in this video. He says he "trusted the third party company" and vaguely references seeing lab results online. That is not the same as independently verified certificate of analysis data.
What should you actually know?
Retatrutide is not FDA-approved. It is not legally dispensed as a prescription compound in the United States. Purchasing it from peptide vendors means you are buying an unregulated research chemical with no guaranteed purity, sterility, or concentration accuracy. The Phase 2 data from Jastreboff et al. is genuinely compelling — up to 24 percent body weight reduction at 48 weeks in some dose groups — but that trial used pharmaceutical-grade drug with medical oversight and a slow titration schedule.
Self-injection of a GIP/GLP-1/glucagon agonist without baseline labs, without cardiovascular screening, and without a titration protocol is not the same thing as participating in a clinical trial. Pancreatitis, tachycardia, and severe GI events were among the adverse effects noted in the Phase 2 data. None of that is mentioned in a 60-second reconstitution TikTok reaching 1.2 million people.
If you are interested in GLP-1 class therapy for weight management, a regulated telehealth provider can evaluate whether FDA-approved options like semaglutide or tirzepatide are appropriate for your situation, with actual medical oversight.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @aaron.endres's peptide reconstitution tips, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Supports SELECT-context pages where semaglutide claims touch long-term weight change and cardiovascular-risk populations.
PubMed
Semaglutide for cardiovascular event reduction in people with overweight or obesity
Baseline SELECT source for cardiovascular-outcomes framing in people with overweight or obesity.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
@aaron.endres's peptide reconstitution tips, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The video demonstrates reconstitution of what is almost certainly retatrutide (LY3437943), a triple receptor agonist in Phase 3 clinical trials that is not FDA-approved or legally available as a compounded prescription in the U.
FormBlends verdict
The video demonstrates reconstitution of what is almost certainly retatrutide (LY3437943), a triple receptor agonist in Phase 3 clinical trials that is not FDA-approved or legally available as a compounded prescription in the U.S. The creator's concentration math (20 units per milligram from a 5mg vial in 1mL bac water) is arithmetically correct, but his verbal explanation is garbled in a way that creates real dosing confusion risk. Retatrutide's dose-dependent adverse event profile, including nausea, vomiting, and potential cardiovascular effects, makes unmonitored self-dosing based on a social media video a meaningful safety concern.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video demonstrates reconstitution of what is almost certainly retatrutide (LY3437943), a triple receptor agonist in Phase 3 clinical trials that is not FDA-approved or legally available as a compounded prescription in the U.S. The creator's concentration math (20 units per milligram from a 5mg vial in 1mL bac water) is arithmetically correct, but his verbal explanation is garbled in a way that creates real dosing confusion risk. Retatrutide's dose-dependent adverse event profile, including nausea, vomiting, and potential cardiovascular effects, makes unmonitored self-dosing based on a social media video a meaningful safety concern.
- Retatrutide is not FDA-approved and is not legally available as a compounded prescription in the United States as of 2024.
- Jastreboff et al. 2023 (NEJM) showed up to 24 percent body weight reduction with retatrutide in Phase 2, but all dosing was medically supervised with a slow titration protocol over many weeks.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Retatrutide is not FDA-approved and is not legally available as a compounded prescription in the United States as of 2024.
- Jastreboff et al. 2023 (NEJM) showed up to 24 percent body weight reduction with retatrutide in Phase 2, but all dosing was medically supervised with a slow titration protocol over many weeks.
- The reconstitution technique shown (bac water down the vial wall, gentle rotation, no shaking) is technically sound and consistent with standard peptide handling practice.
- The creator's dose calculation contains a verbal error that could cause viewers to misidentify their concentration, and a dosing mistake with a GLP-1/GIP/glucagon agonist can cause serious GI or cardiovascular adverse events.
- Unregulated peptide vendors are not subject to FDA Current Good Manufacturing Practice rules, meaning purity, sterility, and labeled concentration are unverified claims.
- Phase 2 adverse events for retatrutide included nausea in up to 60 percent of participants at higher doses, plus vomiting, diarrhea, and tachycardia, none of which were mentioned in this video.
- FDA-approved GLP-1 receptor agonists prescribed through a regulated medical provider represent a legal, clinically monitored alternative for people interested in this drug class for weight management.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Aaron Endres · TikTok creator
1.2M views on this video
How to reconstitute 🐀-a so you don’t mess it up! Nova peps code ACE
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Aaron Endres, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.